bluebird bio Inc
NASDAQ:BLUE

Watchlist Manager
bluebird bio Inc Logo
bluebird bio Inc
NASDAQ:BLUE
Watchlist
Price: 4.97 USD Market Closed
Market Cap: 48.7m USD

BLUE's latest stock split occurred on Dec 13, 2024

The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.

Before the split, BLUE traded at 0.38 per share. Afterward, the share price was about 6.34.

The adjusted shares began trading on Dec 13, 2024. This was BLUE's 2nd stock split, following the previous one in Nov 5, 2021.

Last Splits:
Dec 13, 2024
1-for-20
Nov 5, 2021
1544-for-1000
Pre-Split Price
7.6 0.38
Post-Split Price
6.34
Before
After
Last Splits:
Dec 13, 2024
1-for-20
Nov 5, 2021
1544-for-1000

bluebird bio Inc
Stock Splits History

BLUE Stock Splits Timeline
Dec 13, 2024
Dec 13, 2024
Split 1-for-20
/0.05
Pre-Split Price
7.6 0.38
Post-Split Price
6.34
Before
After
Nov 5, 2021
Nov 5, 2021
Split 1544-for-1000
x1.544
Pre-Split Price
326.1334 25.1775
Post-Split Price
262.8
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
46.07 46.07 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
58.88 58.88 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
51.129 51.129 USD N/A
Load More

bluebird bio Inc
Glance View

Market Cap
48.7m USD
Industry
Biotechnology

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 518 full-time employees. The company went IPO on 2013-06-19. The firm is principally focused on researching, developing and commercializing gene therapies for genetic diseases. The Company’s programs in genetic diseases include betibeglogene autotemcel (beti-cel) as a treatment for transfusion-dependent B-thalassemia (TDT); LentiGlobin product candidate as a treatment for sickle cell disease (SCD), and elivaldogene autotemcel (eli-cel) as a treatment for cerebral adrenoleukodystrophy (CALD). The company develops LentiGlobin gene therapy for patients with SCD, a hereditary blood disorder resulting from a mutation in the b-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. The beti-cel is marketed as ZYNTEGLO for the treatment of adult and adolescent patients with TDT in the European Union. Its product candidate also include SKYSONA for the treatment of patients with CALD in the European Union, Iceland, Liechtenstein and Norway.

BLUE Intrinsic Value
Not Available
Back to Top